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Abstract
Background: Primaquine, the only available drug effective against Plasmodium falciparum sexual stages, induces
also a dose-dependent haemolysis, especially in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals.
Therefore, it is important to determine the prevalence of this deficiency in areas that would potentially benefit from
its use. The prevalence of G6PD deficiency by genotype and enzyme activity was determined in healthy school
children in The Gambia.
Methods: Blood samples from primary school children collected during a dry season malaria survey were screened
for G6PDd and malaria infection. Genotypes for allele mutations reported in the country; 376, 202A-, 968A- and 542
were analysed while enzyme activity (phenotype) was assayed using a semi-quantitative commercial test kit. Enzyme
activity values were fitted in a finite mixture model to determine the distribution and calculate a cut-off for deficiency.
The association between genotype and phenotype for boys and girls as well as the association between mutant
genotype and deficient phenotype was analysed.
Results: Samples from 1,437 children; 51% boys were analysed. The prevalence of P. falciparum malaria infection
was 14%. The prevalence of the 202A-, 968 and 542 mutations was 1.8%, 2.1% and 1.0%, respectively, and higher
in boys than in girls. The prevalence of G6PDd phenotype was 6.4% (92/1,437), 7.8% (57/728) in boys and 4.9%
(35/709) in girls with significantly higher odds in the former (OR 1.64, 95% CI 1.05, 2.53, p = 0.026). The deficient
phenotype was associated with reduced odds of malaria infection (OR 0.77, 95% CI 0.36, 1.62, p = 0.49).
Conclusions: There is a weak association between genotype and phenotype estimates of G6PDd prevalence.
The phenotype expression of deficiency represents combinations of mutant alleles rather than specific mutations.
Genotype studies in individuals with a deficient phenotype would help identify alleles responsible for haemolysis.
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Background
The reduction in the malaria burden observed in several
endemic countries has revived optimism about the pos-
sible elimination of this disease [1-3]. In this context, the
prospect of a massive scale up of control interventions,
including the use of drugs active against sexual stages of
Plasmodium falciparum with the aim of interrupting
transmission, is of particular interest [4]. Currently,
primaquine, an 8-aminoquinoline, is the only available
medicine with gametocytocidal properties and its ad-
ministration with artemisinin-based combination therapy
(ACT) is recommended in areas where malaria elimin-
ation is considered feasible [5]. Nevertheless, primaquine
may cause haemolytic anaemia in individuals with glu-
cose-6-phosphate dehydrogenase deficiency (G6PDd), a
major bottleneck for its large-scale use [6,7]. Therefore,
the decision to deploy primaquine should be based on the
local prevalence of G6PDd and on the evaluation of the
potential risks of adverse drug reactions.
G6PDd is considered the most common enzyme defi-
ciency, affecting about 5% of the world’s population, though
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in most cases it is clinically silent [8]. It is caused by
mutations in the coding sequence of the gene located
on the X- chromosome and thus affects mainly males
when hemizygous, while females can be either homo- or
heterozygous for this deficiency. G6PDd protects against
severe malaria and there is a significant geographical
overlap with malaria endemic areas [9,10]. Therefore,
the use of primaquine represents an ethical challenge
as those who could benefit the most may also be at
greatest risk of harm [11]. Information on the prevalence
of G6PDd is fragmented; in sub-Saharan Africa (sSA),
prevalence figures have been generated using different
methods so that it is difficult to compare and summarize
the available information [10,12-16]. In addition, as detec-
tion methods have improved over the years, some G6PDd
prevalence figures may need to be reviewed.
G6PD status is determined by molecular and/or bio-
chemical methods [17]. Screening tests involve either quan-
titative or qualitative measurements of enzyme activity
but are affected by several factors [18] and have reduced
sensitivity in detecting heterozygous females [19]. Molecu-
lar methods provide more consistent results but are costly.
Besides the wild type (G6PD B), the G6PD A variant is
considered the most prevalent and the most studied in
sSA [20]. This G6PD A variant is polymorphic, charac-
terized by amino acid replacements that include the
G6PD A (376G) mutation, A-(202A), A-(968C) and A-
(680T). Other variants have been reported from studies
of preselected population [10] and appear to be more
clustered, with even higher prevalence than the classic
202A- [12], highlighting the need for a better description
of the burden of this enzyme deficiency.
This study presents an update on G6PD genotype fre-
quencies reported in The Gambia and describes the
association between genotypes and phenotypes (enzyme
activity) in healthy school children.
Methods
As part of a malariometric survey [21], blood samples
from children aged 5 to 14 years were analyzed for both
specific G6PD mutations (genotype) and enzyme activity
(phenotype). Briefly, clinically healthy children were
randomly selected from 32 lower basic schools in the
Upper River Region of The Gambia. After a clinical
assessment, a finger prick blood sample was collected
onto a Whatman filter paper for G6PD assay and parasite
detection by polymerase chain reaction (PCR). Haemoglo-
bin was measured using a portable haemoglobin analyser
(Hemocue, Angelholm, Sweden). Children with a history
of fever or body temperature ≥37.5°C were screened for
malaria using a rapid antigen test kit (ICT Diagnostics,
South Africa) and if positive, treated with artemether-
lumefantrine. The filter papers were air dried and stored
at 4°C until processed. The Gambia Government/MRC
joint ethics committee and the national education author-
ity approved the study. An informed consent was obtained
from parents/ caregivers of selected children.
Measuring G6PD enzyme activity
Enzyme activity was measured using a commercial quanti-
tative ELISA kit (Atlas Medical®). It is based on the spec-
trophotometric measurement of reduced nicotinamide
adenine dinucleotide phosphate (NADPH) released during
G6PD enzyme activity and, colorimetrically by reduction
of tetrazolium salt (550 nm). The readings from the 340 nm
measurement were used in the calculations. A 6 mm diam-
eter disc was punched from each dried blood spot (DBS)
into a U bottom microtitre plate and eluted with 75 μL
of elution agent. NADPH was measured as absorbance
at 340 nm [22] in kinetic mode for 15 minutes. Enzyme
activity was normalized against the protein content of
blood spot eluents determined by measuring absorbance
Table 1 Prevalence of mutant alleles by gender
Allele type Female (%) N = 709 Male (%) N = 728
Wild 281 (39.6) 436 (59.9)
202A-(H) 50 (7.1) -
202A-(M) 2 (0.3) 24 (3.3)
968 (H) 24 (3.4) -
968 (M) 4 (0.6) 26 (3.6)
542 (H) 18 (2.5) -
542 (M) 2 (0.3) 12 (1.7)
Others* 328 (46.3) 230 (31.6)
M=Mutant, H = Heterozygote.
*Including single, double and triple mutations (see Table 2).
Table 2 Prevalence of other observed alleles by gender
Allele type Female (%) N = 328 Male (%) N = 230
Single 542H 2 (0.6) -
968H 1 (0.3) -
202H 188 (57.3) -
376H 9 (2.7) -
202M 90 (27.4) 215 (93.5)
376M 2 (0.6) 7 (3.0)
968M - 5 (2.2)
542M - 3 (1.3)
Double 202H/542M 3 (0.9) -
202H/376M 1 (0.3) -
202M/542H 9 (2.7) -
202M/968H 4 (1.2) -
202M/376H 15 (4.6) -
Triple 202H/376H/542H 2 (0.6) -
202M/376H/542H 2 (0.6) -
M=Mutant, H = Heterozygote.
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of haemoglobin at 405 nm and expressed as the normal-
ized increase in OD per minute (slope) using the following
equation: (ΔOD340nm/Δtime)/OD405nm.
G6PD genotyping
DNA was extracted using protocols for the QiaExtracto-
gen liquid handling robot (QiaGen). Allele polymorphisms
were detected by real-time PCR with TaqMan® SNP geno-
typing assays using ABI PRISM SDS 7500 (Applied Bio-
systems, Foster City, CA). Oligonucleotide primers and
probe genotyping assay mixes for nucleotides A376G,
G202A, A542T and T968C, were also obtained from
Applied Biosystems. Genotyping assay were performed in
a final reaction of 25 μL, containing 12.5 μL of 2× TaqMan
Universal Master Mix, 0.5 μL of 40× TaqMan SNP geno-
typing assay mix and at least 10ηg of genomic DNA in
11 μL of distilled water. The amplification conditions were
2 minutes at 50°C for AmpErase uracil-N-glycosylase
activity and 10 minutes at 95°C for Amplitaq Gold acti-
vation, followed by 40 cycles of 15 seconds at 95°C for
denaturation and 1 min at 60°C for annealing and exten-
sion. The samples were run together with the non-template
control. Allelic discrimination was performed on fluores-
cence data using the ABI Prism 7500 allelic discrimination
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Figure 1 Distribution of G6PD activity in boys (a) and girls (b).
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software and the free TaqMan-Genotyper Software (Ap-
plied Biosystems, Foster City, CA). Each sample result was
verified by examining the PCR curve generated to eliminate
false-positive results due to aberrant light emission.
Analysis
Children were classified on the basis of allelic discrimin-
ation patterns as normal, mutant (hemi- or homozygous)
or heterozygous (females only) while genotypes were
defined for each of the polymorphic A variants; 376, 202,
968, and for the 542 variant. The distribution of G6PD
enzyme activity in the sample was analysed using a two-
component finite mixture model. Using the population
with the higher mean activity as reference, the cut-off
for activity in the sample was defined as < −2SD below
the mean of this subpopulation. The association between
G6PD activity and allele mutation in males and females
was examined using Pearson χ2. A logistic regression
model was used to determine the relationship between
allele mutation and a deficient phenotype and the asso-
ciation between haemoglobin, gender and parasitaemia
on deficient phenotype. Data was analysed using Stata
12 (College Station Tx).
Results
Blood samples from 1,437 children; 728 (50.7%) of them
boys were analysed. The mean age was 10 years (SD 2.3)
and mean haemoglobin was 12.4 g/dl (SD 1.3), with no
difference between males and females. The prevalence of
malaria infection (all P. falciparum) determined by PCR
was 14% [21]. Overall, 717 (49.9%) children did not have
any mutant alleles and were classified as wild type while
162 (11.3%) were either heterozygous or homo/hemizygous
for the typed variants (Table 1). Among the remaining 558
children, a single mutation was found in 522 of them,
32 had double and four triple mutations (Table 2).
The prevalence of the 202A-, 968 and 542 mutations
was 1.8%, 2.1% and 1.0%, respectively, and higher in boys
than in girls (Table 1).
The median G6PD activity was 0.0028 (IQR 0.0020,
0.0040) and did not vary by gender however, the distribu-
tion in females showed two peaks of activity (Figures 1a
and b). From the analysis, a two-component model pro-
vided the best fit for the data and the threshold for normal
activity was estimated at 0.0010. The estimated prevalence
of the deficient phenotype was 6.4% (92/1437), with higher
frequency in boys (7.8%, 57/728) than in girls (4.9%,
35/709) with an increased odds of a deficient phenotype
in boys (OR 1.64, 95% CI 1.05, 2.53, p = 0.026). The odds
of a malaria infection was not significantly lower in chil-
dren with a deficient phenotype (OR 0.77, 95% CI 0.36,
1.62, p = 0.49). The prevalence of the deficient phenotype
was higher in boys with any of the studied deficient
genotypes and in girls with a 968 or with a 542
mutations (hetero and homozygous) (Table 3). In boys,
the odds of having a deficient phenotype were signifi-
cantly associated with any of the mutations (Table 4). The
odds of a deficient phenotype remained higher in boys
after adjustment for the different genotypes studied
though the strength of this association was weak (OR
1.40, 95%CI 0.86, 2.28, p = 0.175).
Discussion
The use of primaquine in malaria endemic areas should
be balanced by the potential risk of haemolysis in G6PDd
individuals hence the need for accurate estimates of the
prevalence of deficiency.
The 202A- variant is considered the most frequent in
sSA so that the prevalence of G6PDd is often measured by
detecting this mutation. Nevertheless, in this area the
968A- variant was more frequent than the 202A- variant,
confirming previous reports [10,12] and indicating that
allele mutations related to G6PDd status may show distinct
sub-regional distribution. A range of factors including clin-
ical status, medication and undiagnosed haemoglobinopa-
thies affects G6PD activity [6,23]. Children attending school
were chosen in this study because they were considered
clinically healthy at the time of sampling. The prevalence of
malaria infection was 14%, a relatively substantial value
Table 3 Prevalence of the deficient phenotype by
genotype and gender
Deficient phenotype
Genotype Females %(n/N) Males %(n/N)
Wild 5.0 (14/281) 6.2 (27/436)
A-(H) 6.0 (3/50) -
A-(M) 0.0 (0/2) 16.7 (4/24)
968 (H) 4.2 (1/24) -
968 (M) 25.0 (1/4) 30.8 (8/26)
542 (H) 11.1 (2/18) -
542 (M) 50.0 (1/2) 25.0 (3/12)
Others 4.0 (13/328) 6.5 (15/230)
Table 4 Odds ratios (95% CI) of a deficient phenotype by
allele mutations and gender
Females (709) Males (728)
Genotype OR P OR P
Wild 1 1
A-(H) 1.22 (0.34, 4.40) 0.76 - -
A-(M) - - 3.03 (0.97, 9.49) 0.057
968 (H) 0.83 (0.10, 6.59) 0.86 - -
968 (M) 6.36 (0.63, 65.08) 0.12 6.73 (2.68, 16.88) 0.00
542 (H) 2.38 (0.49, 11.4) 0.28 - -
542 (M) - - 5.05 (1.29, 19.74) 0.02
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when considering that the survey was carried out at the
end of the dry season, after several months of virtually no
transmission.
G6PDd has been associated with a protective effect
against severe malaria [24] in males but not in females
[25] and has been associated with multiple mutations
rather than a specific mutant genotype [10]. However,
its effect on asymptomatic infection is less clear. In this
study, G6PDd showed a weak association with asymp-
tomatic infection and this is similar to observations in
other studies assessing the effect of haemoglobinopathies,
including G6PDd [26,27].
Measuring single genotypes [28-30] does underestimate
the true G6PDd prevalence because it targets only the
individual genotypes known to be highly frequent in the
study population. From this study, about 39% of the chil-
dren had a range of single or multiple allele mutations
that did not fit any of the combinations that characterize
the studied genotypes. These mutations cause qualitative or
quantitative changes in enzyme activity that range from no
to increased activity and would explain the varied clinical
responses in individuals exposed to potentially haemolytic
agents. There is some evidence that even where enzyme
levels are low, they are never completely absent [31].
Two peaks were seen in the distribution of activity in
females but not in males, which has been described with
the more sensitive cytochemical assays [17,32]. The wide
distribution reflects the mosaicism in normal and deficient
cells and may not be fully explained by heterozygosity
alone. This effect may be due to cells with mutations that
cause increased activity [20] or other untyped mutations
[32]. Cytochemical assays on the other hand are more reli-
able but more expensive.
For mass screening campaigns, qualitative testing is a
feasible option as genotype methods are unlikely to be
used routinely. However, newer methods, potentially
adaptable for high throughput screening and addressing
the limitation in females should be considered.
Conclusion
The prevalence of G6PD deficiency and the risk of
primaquine-induced haemolysis are important for decid-
ing on the use of primaquine. The prevalence of G6PDd
determined by measuring the phenotype (enzyme activ-
ity) is higher than that by genotype (mutations) analysis,
though a substantial proportion of children are positive
for both methods. Phenotype-based screening should
be encouraged while genotype testing could be used to
investigate subjects developing haemolysis but not identi-
fied as G6PDd by the qualitative tests.
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